PAR 12.7% 31.0¢ paradigm biopharmaceuticals limited..

research reports and media, page-3511

  1. 696 Posts.
    lightbulb Created with Sketch. 128
    Where is 2027 coming from?

    I'm guessing just a general bearishness but the latest schedule; one were told is conservative, has NDA completion end 2025 and that was pre fast track and certainly discounts the possibility of accelerated approval.

    I feel like you're constructing an argument for the US listing or depository receipts arrangement that you're keen on but I for one don't see the situation quite so bleakly.
 
watchlist Created with Sketch. Add PAR (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.